BriaCell Therapeutics Corp.
BCTX
$2.02
-$0.05-2.42%
NASDAQ
| 04/30/2025 | 01/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 2.09% | -0.17% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -11.73% | 39.14% | |||
| Operating Income | 11.73% | -39.14% | |||
| Income Before Tax | 1.78% | -8.72% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 1.78% | -8.72% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 111.21% | 71.22% | |||
| Net Income | 2.61% | -8.43% | |||
| EBIT | 11.73% | -39.14% | |||
| EBITDA | 11.78% | -39.34% | |||
| EPS Basic | 29.62% | 28.66% | |||
| Normalized Basic EPS | 29.98% | 28.78% | |||
| EPS Diluted | 29.62% | 29.38% | |||
| Normalized Diluted EPS | 29.98% | 28.78% | |||
| Average Basic Shares Outstanding | 38.37% | 52.00% | |||
| Average Diluted Shares Outstanding | 38.37% | 52.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||